Literature DB >> 19414334

Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells.

Ying Sun1, Ehrentraud J Eichelbaum, William P Skelton, Anne Lenz, Hai Wang, David L Vesely.   

Abstract

BACKGROUND: Vessel dilator and kaliuretic peptide have anticancer effects in human prostate adenocarcinomas.
MATERIALS AND METHODS: The effects of vessel dilator, kaliuretic peptide and cyclic GMP on Ras were examined in human prostate adenocarcinoma cells.
RESULTS: Vessel dilator and kaliuretic peptide decreased the activation of Ras -GTP over a concentration range of 0.01 microM to 1 microM. Vessel dilator and kaliuretic peptide (each 1 muM) inhibited the phosphorylation of Ras by 95% (p<0.0001) and 90% (p<0.0001), respectively. At 0.01 microM of kaliuretic peptide, the maximal inhibition was 95% . The inhibition of Ras lasted for 48 to 72 hours secondary to both peptides. Their ability to inhibit Ras was inhibited by cyclic GMP antibody and cyclic GMP itself inhibited Ras phosphorylation (89%; p=0.0015).
CONCLUSION: Vessel dilator and kaliuretic peptide both inhibit Ras partially mediated via cyclic GMP as part of their anticancer mechanism(s) of action.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414334

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Potent selective inhibition of STAT 3 versus STAT 1 by cardiac hormones.

Authors:  Meghan L Lane; Chelsea D Frost; Jennifer P Nguyen; William P Skelton; Michelle Skelton; David L Vesely
Journal:  Mol Cell Biochem       Date:  2012-09-11       Impact factor: 3.396

2.  Effects of Atrial Natriuretic Peptide on p53 and Estrogen Receptor in Breast Cancer Cells.

Authors:  Katie Aleck; Kelly Hallman; Meghan Quigley; Victoria Lloyd; Monica Szmyd; Dana Ruskin; Tyler Bedgood; Sumi Dinda
Journal:  Biores Open Access       Date:  2017-10-01

Review 3.  Evaluation of the use of therapeutic peptides for cancer treatment.

Authors:  Susan Marqus; Elena Pirogova; Terrence J Piva
Journal:  J Biomed Sci       Date:  2017-03-21       Impact factor: 8.410

4.  Cardiac Hormones Target the Ras-MEK 1/2-ERK 1/2 Kinase Cancer Signaling Pathways.

Authors:  David L Vesely
Journal:  Cancers (Basel)       Date:  2011-03-08       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.